Skip to main content

Search This Blog

Prostate Cancer

Posts

Showing posts from March, 2026

Laryngeal cancer: What you should know

Get link
Facebook
X
Pinterest
Email
Other Apps

- March 01, 2026

Invalid Access Key! Invalid Access Key!

Ministrokes and cancer: 9 questions answered

Get link
Facebook
X
Pinterest
Email
Other Apps

- March 01, 2026

Invalid Access Key! Invalid Access Key!

10 things to know about neuroendocrine tumors

Get link
Facebook
X
Pinterest
Email
Other Apps

- March 01, 2026

Invalid Access Key! Invalid Access Key!

5 questions to ask a medical oncologist during your first visit

Get link
Facebook
X
Pinterest
Email
Other Apps

- March 01, 2026

Invalid Access Key! Invalid Access Key!

What men need to know about HPV-related throat cancer (oropharyngeal cancer)

Get link
Facebook
X
Pinterest
Email
Other Apps

- March 01, 2026

Invalid Access Key! Invalid Access Key!

Powered by Blogger

Theme images by billnoll

Popular Posts

Expert Discusses Data From First Positive Trial for PARP Inhibitor in Prostate Cancer - Targeted Oncology

- November 05, 2019

Alan Bryce, MD PARP inhibition with olaparib (Lynparza) improved radiographic progression-free survival (rPFS) in heavily pretreated patients with metastatic castration-resistant prostate cancer (mCRPC) who had alterations in homologous recombination repair (HRR) genes, according to findings from the phase III PROfound trial presented at the 2019 ESMO Congress. This was the first positive randomized phase III trial reported evaluating a PARP inhibitor in men with mCRPC. The PROfound trial enrolled patients to 2 cohorts. In cohort A, 245 patients with BRCA1/2 or ATM alterations, markers of HRR, were randomized 2:1 to receive either olaparib (n = 162) or physician’s choice of abiraterone acetate (Zytiga) with prednisone or enzalutamide (Xtandi) (n = 83). In cohort B, 142 patients with alterations in the BARD1, BRIP1, CDK12, CHEK1/2, FANCL, PALB2, PPP2R2A, RAD51B/C/D , or RAD54L , all of which are associated with HRR indirectly, were also randomized 2:...

Sentinel lymph node biopsy: What cancer patients should know

cancer lump on neck :: Article Creator Doctor Watching TV Show Spotted Cancer On Show's Guest That She Didn't Know About Say what you will about social media and daytime TV, but sometimes, they can help work wonders. In fact, the power of Facebook and the popularity of HGTV's Beachfront Bargain Hunt played a big part in helping Nicole McGuiness get ahead of her serious cancer diagnosis - but it was an eagle-eyed doctor who really saved her bacon. The then-32-year-old appeared on the property series alongside her father while in search of a holiday home in North Carolina to celebrate her recent recovery from brain cancer in May 2018. She explained that she had set her sights on 'something near the water', specifically a beachfront property in Morehead City, to start afresh in this new phase of her life. Dr. Erich Voigt was one of the viewers who tuned into the Beachfront Bargain Hunt episode, which Nicole featured in, an...

What to know about castor oil health claims

- February 05, 2026

Invalid Access Key! Invalid Access Key!

Tumor biomarkers for diagnosis, prognosis and targeted therapy | Signal Transduction and Targeted Therapy

- February 03, 2026

Invalid Access Key! Invalid Access Key!

Cancer Glossary | Definitions & Phonetic Pronunciations

- February 04, 2026

Invalid Access Key! Invalid Access Key!

Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised ...

- October 22, 2018

[unable to retrieve full-text content] Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised ... The Lancet New prostate cancer approach may add years NEWS.com.au New approach to prostate cancer treatment could help thousands of men BT.com Full coverage https://ift.tt/2R75OGL

What are the top 5 warning signs of prostate cancer?

- November 03, 2024

hcc treatment :: Article Creator TARE In Advanced HCC: When Is It Optimal And Why? Jin Woo Choi, MD, PhDSeoul National University Hospital Seoul National UniversitySeoul, Republic of Koreajwchoi.Med@snu.Ac.KrDisclosures: None. Transarterial radioembolization (TARE) can be considered for patients with unilobar hepatocellular carcinoma (HCC) and ipsilateral portal vein tumor thrombosis (Vp1-3), provided there is no hepatic vein invasion, no extrahepatic spread, Child-Pugh A status, and an ECOG (Eastern Cooperative Oncology Group) performance status of 0 to 1. Although this represents an advanced stage of HCC, locoregional treatments may still be viable, and an effective locoregional treatment can potentially increase the likelihood of curative outcomes. Despite the rapid development of immune checkpoint inhibitors, which are now the frontline treatment for advanced HCC, there is a significant lack of detailed data for this specific patient popul...

Brain Tumor: Types, Signs, Symptoms, and Treatment

- January 29, 2026

Invalid Access Key! Invalid Access Key!

'Bold' Prostate Cancer Trial Enrolls 'Very, Very Quickly' - Medscape

- April 29, 2020

Once the stuff of headlines and clinical buzz, sipuleucel-T ( Provenge , Dendreon) has had a steep decline in its profile as a prostate cancer treatment. But the stage is being set for a possible comeback. To much fanfare in 2010, the drug became the first-ever immunotherapy for metastatic prostate cancer to be approved by the US Food and Drug Administration, albeit in a protracted and controversial process. In the final data set, it improved overall survival by 4 months compared with placebo. It is an unusual product. Sometimes referred to as a vaccine and usually called by its trade name, Provenge is an autologous active cellular immunotherapy, made individually for each patient. Clinical uptake of the product was slow, and, after launch, it soon faced stiff competition from other new drugs for advanced disease. Ten years after approval, the once-hyped therapy is now seldom mentioned, and, according to the company, has only 8% penetration of the metastatic prostate cancer ma...

Tumor biomarkers for diagnosis, prognosis and targeted therapy | Signal Transduction and Targeted Therapy

- February 05, 2026

Invalid Access Key! Invalid Access Key!

Archive

March 20265
February 202677
January 202687
December 2025102
November 202572
October 202569
September 202598
August 202598
July 202585
June 202596

Show more Show less

Labels

"cancer prostata" - Google News
"metastatic prostate cancer" - Google News
"prostate cancer causes" - Google News
"prostate cancer survival rate" - Google News
"prostate cancer treatment options" - Google News
"prostate cancer treatment" - Google News
"prostate cancer" - Google News
"prostatectomy" - Google News
"symptoms of prostate cancer in men" - Google News
cancer+prostata - Google News

Google News
IFTTT
metastatic prostate cancer
metastatic+prostate+cancer - Google News
prostate cancer
prostate cancer causes
prostate cancer survival rate
prostate cancer treatment
prostate cancer treatment options
prostate+cancer - Google News
prostate+cancer+causes - Google News
prostate+cancer+survival+rate - Google News
prostate+cancer+treatment - Google News
prostate+cancer+treatment+options - Google News
prostatectomy
prostatectomy - Google News
symptoms of prostate cancer in men
symptoms+of+prostate+cancer+in+men - Google News

Show more Show less